I-Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of umdlavuza we-thyroid.
U-Eisai uthe i-Lenvima izoba indinganiso entsha yokwelashwa komdlavuza wegilo ongalungiseki. Imboni inethemba elikhulu nge-Lenvima, futhi kulindeleke ukuthi lesi sidakamizwa sibe inkomo entsha yemali yakwa-Eisai, lapho ukuthengiswa kwaminyaka yonke kukhuphuka ngaphezu kwe- $ 1 billion.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved isisu volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
Njengamanje, nakuba izinhlobo eziningi zomdlavuza wegilo zingelashwa, zimbalwa izindlela zokwelapha uma ziba zimbi kakhulu. I-Differential thyroid cancer (DTC) iyithumba legilo eliyingozi elivame kakhulu, futhi izinga layo liye landa kancane kancane eminyakeni yamuva.
I-Lenvatinib iyi-oral multi-receptor tyrosine kinase (RTK) inhibitor enemodi yokubopha inoveli. Ngokungeziwe ekuvimbeleni amanye ama-RTK ahilelekile ekwandeni kwesimila kanye nezindlela zokusayina ze-oncogenic, futhi ingavimbela ngokukhetha umsebenzi we-vascular endothelial growth factor (VEGF) receptor kinase.
